既往甲减患者发生Graves病的临床特征与结局
这项回顾性队列研究比较了既往甲减后发生Graves病(post-hypo-GD)与无既往甲状腺疾病的Graves病对照。post-hypo-GD患者年龄更大、女性比例更高、自身免疫病更常见,甲亢程度更轻,抗甲状腺药物使用更少,但随访结束时需要左甲状腺素的甲减发生率是对照的两倍以上。
要点
- 既往甲减后发生Graves病约占新发Graves病的10%,以女性为主。
- 该类患者甲亢程度更轻,抗甲状腺药物使用率更低。
- 随访结束时甲减复发需左甲状腺素的风险是对照的两倍以上。
核心结论
- 既往甲减后发生的Graves病是一种独特的表型,以女性为主,甲亢程度较轻,抗甲状腺药物使用较少,且甲减复发率高。
- 建议常规评估既往甲状腺状态并进行密切的生化监测。
研究设计与样本
- 回顾性队列研究,纳入2010年至2022年期间以色列Maccabi Healthcare Services的成人 incident Graves病患者,随访至2024年10月。
- 共纳入2402例患者,其中post-hypo-GD 256例,Graves病对照2146例;排除既往或当前使用胺碘酮者。
主要发现
- 与Graves病对照相比,post-hypo-GD患者年龄更大(51.4 ± 14.3 vs 47.4 ± 13.6岁,P < .001),女性比例更高(88.2% vs 76.9%,P < .001),自身免疫病患病率更高(19.5% vs 12.9%,P = .003)。
- 诊断时post-hypo-GD患者疾病更轻,中位游离T4(21.7 vs 26.8 pmol/L,P < .001)和游离T3(8.5 vs 10.4 pmol/L,P < .001)水平更低。
- 中位随访7.2年期间,post-hypo-GD患者接受抗甲状腺药物治疗的比例更低(65.6% vs 81.0%,P < .001);放射性碘消融和全甲状腺切除术的使用率相当。
- 随访结束时,post-hypo-GD患者发生需要左甲状腺素的甲减的风险是对照的两倍以上(41.8% vs 21.0%,P < .001)。
临床怎么用
- 对Graves病患者应常规询问既往甲状腺疾病史,识别post-hypo-GD表型。
- 对此类患者应密切监测甲状腺功能,警惕甲减复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Transition from hypothyroidism to Graves' disease (GD) is uncommon. OBJECTIVE: To compare presentation, management, and outcomes of GD after hypothyroidism (post-hypo-GD) with GD controls (no prior thyroid disease). DESIGN: Retrospective cohort 2010 to 2022, followed through October 2024. SETTING: Maccabi Healthcare Services, Israeli health maintenance organization. PATIENTS: Adults with incident GD and thyroid-stimulating immunoglobulin activity ≥140% within 1 year of thyrotoxicosis (N = 2402, 256 post-hypo-GD, 2146 GD controls). Excluded prior or current amiodarone users. INTERVENTIONS: Longitudinal assessment of usual care with antithyroid drugs, radioactive iodine, or total thyroidectomy, and subsequent hypothyroidism requiring levothyroxine. MAIN OUTCOME MEASURES: Usual care treatments and incident hypothyroidism requiring levothyroxine. RESULTS: Compared to GD controls, post-hypo-GD patients were older (51.4 ± 14.3 vs 47.4 ± 13.6 years, P < .001), predominantly female (88.2% vs 76.9%, P < .001), and with higher prevalence of autoimmune disease (19.5% vs 12.9%, P = .003). At diagnosis, post-hypo-GD patients had milder disease with lower median free T4 (21.7 vs 26.8 pmol/L, P < .001) and free T3 (8.5 vs 10.4 pmol/L, P < .001) levels. Over a 7.2-year median follow-up, post-hypo-GD patients were less frequently treated with antithyroid drugs (65.6% vs 81.0%, P < .001). Radioactive iodine ablation and total thyroidectomy use were comparable. Post-hypo-GD patients were more than twice as likely to develop hypothyroidism requiring levothyroxine at the end of follow-up (41.8% vs 21.0%, P < .001). CONCLUSION: Post-hypo-GD (∼10% of new GD cases) is a distinct, predominantly female phenotype marked by milder thyrotoxicosis, lower antithyroid drug use, and a high rate of relapse into hypothyroidism warranting routine assessment of prior thyroid status and close biochemical monitoring.
引用
- Nakhleh A, Robenshtok E, Adler L, et al. Clinical Characteristics and Outcomes of Graves' Disease in Individuals with Prior Hypothyroidism. J Clin Endocrinol Metab. 2026. PMID: 40709412. doi:10.1210/clinem/dgaf426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。